Ophthalmics Collaboration and Licensing Deals 2019-2024
Ophthalmics Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals | Comprehensive deal directory 2019 to 2024
Ophthalmics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the ophthalmics deals entered into by the worlds leading biopharma companies.
Fully revised and updated, the report provides details of ophthalmics deals from 2019 to 2024.
The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration and licensing deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
The initial chapters of this report provide an orientation of ophthalmics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in ophthalmics dealmaking.
Chapter 3 covers the financial deal terms for deals signed in the ophthalmics field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
Chapter 4 provides a review of the top 25 most active biopharma companies in ophthalmics dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive and detailed review of ophthalmics deals signed and announced since 2019 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of ophthalmics deals listed by theraeutic target.
The report also includes numerous table and figures that illustrate the trends and activities in ophthalmics deal making since 2019.
In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Key benefits
Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse ophthalmics collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Report scope
Ophthalmics Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of ophthalmics trends and structure of deals entered into by leading biopharma companies worldwide.
Ophthalmics Collaboration and Licensing Deals includes:
- Trends in ophthalmics dealmaking in the biopharma industry
- Overview of collaboration and licensing deal structure
- Directory of ophthalmics deal records covering pharmaceutical and biotechnology
- The leading ophthalmics deals by value
- Most active ophthalmics licensing dealmakers
In Ophthalmics Collaboration and Licensing Deals, the available deals are listed by:
- Company A-Z
- Headline value
- Therapeutic area
- Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Ophthalmics Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.
Analyzing contract agreements allows due diligence of:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Ophthalmics Collaboration and Licensing Deals provides the reader with the following key benefits:
- Understand deal trends since 2019
- Browse ophthalmics collaboration and licensing deals
- Benchmark analysis – identify market value of transactions
- Financials terms - upfront, milestone, royalties
- Directory of deals by company A-Z, therapy focus and technology type
- Leading deals by value
- Most active dealmakers
- Identify assets and deal terms for each transaction
- Access contract documents - insights into deal structures
- Due diligence - assess suitability of your proposed deal terms for partner companies
- Save hundreds of hours of research time
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in ophthalmics dealmaking
2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication
Chapter 3 – Financial deal terms for ophthalmics partnering
3.1. Introduction
3.2. Disclosed financials terms for ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates
Chapter 4 – Leading ophthalmics deals and dealmakers
4.1. Introduction
4.2. Most active in ophthalmics partnering
4.3. List of most active dealmakers in ophthalmics
4.4. Top ophthalmics deals by value
Chapter 5 – Ophthalmics contract document directory
5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available
Chapter 6 – Ophthalmics dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by ophthalmics therapeutic target
Deal directory
Deal directory – Ophthalmics deals by company A-Z 2019 to 2024
Deal directory – Ophthalmics deals by technology type 2019 to 2024
Deal type definitions
About Biopharma Research Ltd
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Ophthalmics partnering since 2019
Figure 2: Ophthalmics partnering by deal type since 2019
Figure 3: Ophthalmics partnering by industry sector since 2019
Figure 4: Ophthalmics partnering by stage of development since 2019
Figure 5: Ophthalmics partnering by technology type since 2019
Figure 6: Ophthalmics partnering by indication since 2019
Figure 7: Ophthalmics deals with a headline value
Figure 8: Ophthalmics deals with upfront payment values
Figure 9: Ophthalmics deals with milestone payment
Figure 10: Ophthalmics deals with royalty rates
Figure 11: Active ophthalmics dealmaking activity since 2019
Figure 12: Top ophthalmics deals by value since 2019
Pricing options
- $3,995: single-user (encrypted file - one user/device)
- $5,995: multi-user (encrypted file - up to 5 users/devices)
- $9,995: company (unencrypted file)
Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.
Company license files are not encrypted and can be accessed using a PDF Reader.
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by Evalon.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
3SBio, 4D Molecular Therapeutics, 4P-Pharma, A*STAR Agency for Science, Technology and Research, AAVnerGene, Abbvie, AbCellera Biologics, Abpro, ABVC BioPharma, Accure Therapeutics, ACE Solutech, ActualEyes, Acucela, Adaptive Phage Therapeutics, Aequus Pharmaceuticals, Aerie Pharmaceuticals, AEYE Health, AffaMed Therapeutics, Affilogic, AimMax Therapeutics, AJU Pharma, Aker BioMarine, Alcon Laboratories, Aldeyra Therapeutics, Alexion Pharmaceuticals, Alimera Sciences, Alnylam Pharmaceuticals, Alvotech, Ambiopharm, American Diabetes Association, Angios, Apellis Pharmaceuticals, Apexian Pharmaceuticals, Apotex, Applied Genetic Technologies, Arctic Vision, Astellas Pharma, Attillaps Holdings, Aura Biosciences, Aurolab, Avanzanite Bioscience, Avellino Labs, Avista Therapeutics, Axantia, AXIM Biotechnologies, AyoxxA Biosystems, Bascom Palmer Eye Institute, Bausch & Lomb, Bausch Health Companies, Baxter International, Bayer, Beam Therapeutics, Betta Pharmaceuticals, Beyeonics Vision, BHVI, Bio-Techne, BioCryst Pharmaceuticals, Bioeq IP, Biogen, BioLight, BioStem Technologies, Blackrock Neurotech, Blueprint Genetics, BlueRock Therapeutics, Boehringer Ingelheim, Bridge Biotherapeutics, Brigham and Women's Hospital, BVI Medical, C-Bridge Capital, California Institute for Regenerative Medicine, Capsida Biotherapeutics, Carl Zeiss, Carl Zeiss Meditec, Case Western Reserve University, Catalent, Catalyst Biosciences, CDR-Life, Celanese, Cella Therapeutics, Cell Cure Neurosciences, Cellusion, Celregen, Cerevast Therapeutics, Changchun High & New Technology Industries, Chiesi Farmaceutici, Children's Hospital Los Angeles, Children's Medical Research Institute, China Grand Pharmaceutical, China Medical System, Choroideremia Research Foundation, Clarion Medical Technologies, ClearPoint Neuro, Clearside Biomedical, Clover Therapeutics, Coave Therapeutics, Coherus Biosciences, Columbia University, Combangio, Copernicus Therapeutics, Cortigent, Cristalia, CROMA Pharma, CS Pharmaceuticals, Curacle, CureVac, Cyagen Biosciences, Daiichi Sankyo, DelSiTech, Dermira, Diana Davis Spencer Foundation, Digital Diagnostics, Diopsys, doc.ai, DotBio, Dr. Agarwal’s Eye Hospitals, Dr. Reddy's Laboratories, Duke University, Dyno Therapeutics, Eastman Chemical Company, ECM Therapeutics, Eluminex Biosciences, Epimune Diagnostics, Equinox Science, ERS Genomics, eSight, Eton Pharmaceuticals, European Organization for Research and Treatment of Cancer, Everads Therapy, Eversight, Evommune, Evotec, Exonate, EyeCRO, Eyedetec Medical, Eyenovia, EyePoint Pharmaceuticals, Eyevensys, Famy Life Sciences, Fibrogen, Find Therapeutics, Florida Pharmaceutical Products, Forge Biologics, Formosa Pharmaceuticals, ForSeeCon Eye Corporation, Foundation Fighting Blindness, FUJIFILM Cellular Dynamics, Galimedix Therapeutics, Gemini Therapeutics, Genentech, Genosity, Gentex, Glaucoma Research Foundation, Glaukos, Grifols, Gyroscope Therapeutics, Halozyme Therapeutics, HanchorBio, Harrow Health, Harvard Medical School, HealPros, Hemera Biosciences, Hemostemix, Henlius Biotech, Hopstem Biotechnology, Horama, Horizon Discovery, Horizon Europe, Horizon Therapeutics, Hovione, IACTA Pharmaceuticals, Ichor Life Sciences, Ikarovec, Immervision, Immunocore, ImPact Biotech, Indoco, Inflammasome Therapeutics, InformedDNA, InMed Pharmaceuticals, Intas Pharmaceuticals, Intellia Therapeutics, Intratus, IQVIA, IRIS, IRIS International, Israeli National Authority for Technological Innovation, iSTAR Medical, Itrom Pharmaceutical Group, Ivantis, iVeena Delivery Systems, Iveric Bio, Jaeb Center for Health Research Foundation, Janssen Pharmaceuticals, Janssen Research & Development, jCyte, Ji Xing Pharmaceuticals, Johns Hopkins University, Johnson & Johnson Vision, Joslin Diabetes Center, K2M, Kanaph Therapeutics, Kiora Pharmaceuticals, Klinge Biopharma, Kodiak Sciences, Konkuk University, Kowa, Kriya Therapeutics, Kubota Vision, Kuria Therapeutics, Laboratoires Thea, Lansheng Medical, Lantheus Holding, Launch Therapeutics, Lee's Pharmaceutical, Leiden University, LENZ Therapeutics, LGC, LianBio, Lineage Cell Therapeutics, LLamasoft, Lochan, LumiThera, Maastricht University, Magruder Eye Institute, Mannin Research, Marchon Eyewear, Massachusetts Eye and Ear Infirmary, Mawson Infrastructure, Mayo Clinic, McMaster University, mCureX Therapeutics, Medical Food Solutions Research, Medical University of South Carolina, MeiraGTx, Melt Pharmaceuticals, Menicon, Minnetronix, miRagen Therapeutics, MitoChem Therapeutics, Mitsubishi Tanabe Pharma, Mosaic Biosciences, Mundipharma, MyMD Pharmaceuticals, Nanomerics, Nanoscope Therapeutics, Narayana Nethralaya Foundation, NASA, National Cancer Institute, National Eye Institute, National Institutes of Health, National Organization for Rare Disorders, National University of Singapore, Neuraly, Neurolens, Neurophth Therapeutics, Nevakar, NGM Biopharmaceuticals, Nicox, NovaBay Pharmaceuticals, Novaliq, Novartis, Noveome Biotherapeutics, Novotech, NTC, Numab, Ocugen, Ocular Therapeutics, Ocular Therapeutix, Oculis, Oculogenex, Ocumension Therapeutics, Ocuphire Pharma, Odylia Therapeutics, OKKO Health, OKYO Pharma, OliX Pharmaceuticals, Olympic Ophthalmics, Omega Therapeutics, Omeros, ONL Therapeutics, OphtAI, Ophthotech, Opsis Therapeutics, Opthea, Optifye Therapeutics, Optina Diagnostics, Optomed, Opus Genetics, Ora, Orbis, Orbit Biomedical, Osmotica Pharmaceuticals, Otsuka, Oxford BioMedica, Oyster Point Pharma, PanOptica, Perelman School of Medicine, PharmAbcine, Pharmaleads, Phillips-Medisize, Pieris Pharmaceuticals, Pierre Fabre, Ping An Ventures, Plex Pharmaceuticals, Polifarma, PolyPhotonix, PreCerv, Precise Biometrics, Precision Optics, Prevail InfoWorks, Promedica International, ProQR Therapeutics, ProtoKinetix, Provectus Biopharmaceuticals, PTC Therapeutics, Q BioMed, Quotient, Rallybio, Rayner Surgical, Ray Therapeutics, RecensMedical, Regeneron Pharmaceuticals, Regenerx, Regenxbio, Remidio Innovative Solutions, Rentschler Biotechnologie, Resilience, Retinagenix, RetinAI Medical, RetiSpec, ReVision Optics, Revision Skincare, Ribomic, Ripple Therapeutics, Roche, RVL Pharmaceuticals, RxCell, Saban Research Institute of Children's Hospital Los Angeles, Samsara Vision, Samsung Bioepis, Samsung Biologics, SanBio, Sanofi, Santen, Santen Pharmaceutical, Santhera Pharmaceuticals, SATT Conectus Alsace, Schepens Eye Research Institute, Scohia Pharma, Second Sight Medical, Selagine, SemaThera, Senju Pharmaceutical, Senshinkai Eye Institute, Senti Biosciences, Shandong Boan Biological Technology, Shape Therapeutics, SIFI (Societa Industria Farmaceutica Italiana), Sight Sciences, Singapore Eye Research Institute (SERI), Sintetica, SipNose, SiSaf, Skye Bioscience, Slayback Pharma, Societal CDMO, Sonoma Pharmaceuticals, SparingVision, Spark Therapeutics, SpliceBio, Staar Surgical Co, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, State University of New York, StemSight, Stuart Therapeutics, Sun Pharma Advanced Research Company, Sun Pharmaceutical, Surrozen, SwissLens, Sydnexis, Taiwan Liposome Company, TALLC, Tangible Science, Taro Pharmaceuticals, Tarsius Pharma, Tarsus Pharmaceuticals, TeamedOn International, Technological University Dublin, Thea Open Innovation, ThinkCyte, Tianjin CanSino Biotechnology, Tilak Healthcare, Titan Pharmaceuticals, Toolgen, Topcon, Translational Research Institute for Space Health, Trethera, Tufts Medical Center, Tufts University, UCB, Uni-Bio Science, University of British Columbia, University of California Los Angeles, University of Colorado, University of Florida Research Foundation, University of Hong Kong, University of Massachusetts Medical School, University of Miami, University of Minnesota, University of Nebraska, University of Pennsylvania, University of Pennsylvania School of Veterinary Medicine, University of Pittsburgh, ValenzaBio, Verana Health, Versea Ophthalmics, Vial, Viela Bio, ViGeneron, Viridian Therapeutics, Vision Care Group, Vision Essence, Vision Institute, VisionWeb, Visiox Pharma, Visus Therapeutics, Vivani Medical, VivaVision Biotech, Vivior, VSP Optics, Vyluma, Wagner Macula Retina Center, Wakamoto Pharmaceutical, Wake Forest University, Wallace H. Coulter Foundation, WuXi Advanced Therapies, Xbrane Bioscience, Xencor, Xequel Bio, XERIS Pharmaceuticals, Yangtze River Pharmaceutical Group, Ypsomed, Zhaoke (Hong Kong) Ophthalmology Pharmaceutical, Zhonglan Electronic Technology
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.